{
    "guideline_id": "2024CSCO小细胞肺癌诊疗指南- .txt",
    "cancer_info": {
        "cancer_name": "Lung Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Limited-stage SCLC, operable",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Lobectomy + lymph node dissection. For postoperative N0, adjuvant chemotherapy with EP/EC regimen; for N1-2, plus mediastinal radiotherapy.",
            "treatment_line": "Initial therapy",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": "Evidence 2A"
        },
        {
            "clinical_context": "Limited-stage SCLC, inoperable or refuse surgery",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Concurrent chemoradiotherapy with etoposide + cisplatin/carboplatin. Radiotherapy starts in cycle 1-2 of chemotherapy.",
            "treatment_line": "Initial therapy",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Extensive-stage SCLC, first-line treatment for PS 0-2",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Immunotherapy combined with chemotherapy: atezolizumab/serplulimab/adebrelimab + etoposide + carboplatin for 4 cycles → immunotherapy maintenance; or tislelizumab/durvalumab + etoposide + cisplatin/carboplatin for 4 cycles → immunotherapy maintenance. Chemotherapy alone: EP (cisplatin + etoposide), EC (carboplatin + etoposide), or IP (irinotecan + cisplatin).",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "TMB",
                    "status": "High",
                    "testing_guidance": "May predict immunotherapy efficacy, but not required for treatment decision"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Extensive-stage SCLC, consolidation after chemotherapy",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Thoracic radiotherapy for patients with CR/PR after chemotherapy, e.g., 30 Gy/10 fractions, to reduce recurrence risk.",
            "treatment_line": "Consolidation",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Extensive-stage SCLC with brain metastasis",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Asymptomatic: systemic treatment first, then whole-brain radiotherapy (WBRT) ± stereotactic radiotherapy (SRS). Symptomatic: WBRT first (e.g., 30 Gy/10 fractions), then systemic treatment after symptoms stabilize.",
            "treatment_line": "Management",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Recurrent SCLC, sensitive relapse (chemotherapy ended >6 months ago)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Original regimen or topotecan or irinotecan.",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1"
        },
        {
            "clinical_context": "Recurrent SCLC, resistant relapse (≤6 months)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Topotecan or paclitaxel/gemcitabine.",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1"
        },
        {
            "clinical_context": "Recurrent SCLC, third-line and beyond",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Anlotinib or nivolumab/pembrolizumab.",
            "treatment_line": "Third-line and beyond",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Transformed SCLC with systemic rapid progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Standard SCLC chemotherapy (etoposide + platinum).",
            "treatment_line": "For transformed disease",
            "biomarker_requirements": [
                {
                    "biomarker_name": "RB1",
                    "status": "Deleted",
                    "testing_guidance": "Confirm RB1 deletion for diagnosis of transformation"
                },
                {
                    "biomarker_name": "TP53",
                    "status": "Deleted",
                    "testing_guidance": "Confirm TP53 deletion for diagnosis of transformation"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1"
        },
        {
            "clinical_context": "Transformed SCLC with isolated progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Original EGFR-TKI + local treatment (radiotherapy/surgery).",
            "treatment_line": "For transformed disease",
            "biomarker_requirements": [
                {
                    "biomarker_name": "EGFR",
                    "status": "Mutated",
                    "testing_guidance": "Confirm EGFR mutation status prior to treatment"
                }
            ],
            "recommendation_level": "Level III Recommendation",
            "evidence_level": "Evidence 3"
        },
        {
            "clinical_context": "Transformed SCLC with systemic slow progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Standard SCLC chemotherapy ± original EGFR-TKI.",
            "treatment_line": "For transformed disease",
            "biomarker_requirements": [
                {
                    "biomarker_name": "EGFR",
                    "status": "Mutated",
                    "testing_guidance": "Confirm EGFR mutation status if EGFR-TKI is used"
                }
            ],
            "recommendation_level": "Level III Recommendation",
            "evidence_level": "Evidence 3"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "proGRP and NSE are used for diagnosis and efficacy monitoring; TMB may predict efficacy of immunotherapy; MGMT methylation predicts better response to temozolomide; SLFN11 predicts sensitivity to PARP inhibitors; CTCs assist in staging and treatment assessment."
    },
    "tcm_recommendations": [
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "Consider traditional Chinese medicine for managing radiotherapy complications",
            "recommendation_grade": ""
        }
    ]
}